Hanol IP & Law

Min Son of Hanol IP & Law looks at the alternatives available when South Korea does not acknowledge safeguards for missing deadlines as provided in the WIPO’s Patent Cooperation Treaty rules

Min Son of Hanol IP & Law considers the use of a re-filing strategy against non-use cancellation

Min Son of Hanol IP & Law summarises the eligible drugs, the re-examination period and strategies available for companies

Min Son of Hanol IP & Law explains how the recent Supreme Court en banc ruling changes precedents on infringement by the use of later-registered trademarks

Min Son of Hanol IP & Law describes how patent challenges have become even more important under the revised drug pricing framework in South Korea

Min Son of Hanol IP & Law looks at how the Korean Intellectual Property Office (KIPO) and the Korean courts have judged the registrability and validity of pharmaceutical trademarks according to more specific criteria